Indication from A.J. Aamund A/S and Asger Aamund regarding participation in NeuroSearch's rights issue

Not for release, publication or distribution in Australia, Canada, Japan or the
United States. This announcement does not constitute an offer to sell or the
solicitation of an offer to buy the securities of NeuroSearch A/S (the
“Securities”) in Australia, Canada, Japan or the United States or in any other
jurisdiction. Securities may not be offered or sold in the United States absent
registration or an exemption from registration under the U.S. Securities Act of
1933, as amended. The issuer of the Securities has not registered, and does not
intend to register, any portion of the Offering in the United States, and does
not intend to conduct a public offering of the Securities in the United States. 



Announcement


Indication from A.J. Aamund A/S and Asger Aamund regarding participation in
NeuroSearch's rights issue 

NeuroSearch has been made aware that after the announcement yesterday, 31
October 2007 of an Offering Circular in connection with a rights issue from
NeuroSearch, the major shareholder A.J. Aamund A/S (wholly owned by Asger
Aamund) and CEO Asger Aamund made a preliminary decision to exercise their
preemptive rights and subscribe new shares in connection with the offering. 

A.J. Aamund A/S and CEO Asger Aamund at present own 5.13 per cent of the share
capital of NeuroSearch. 



Contacts:

Flemming Pedersen, CEO
Telephone: +45 4460 8214 or +45 2148 0118

Hanne Leth Hillman, Vice President, 
Director of Investor Relations & Corporate Communications
Telephone: +45 4460 8212 or +45 40175103



NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the
OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of
novel drugs, based on a broad and well-established drug discovery platform
focusing on ion channels and CNS disorders. A substantial part of the Company's
activities are partner financed through a broad alliance with GlaxoSmithKline
(GSK) and collaborations with among others Abbott and Astellas. The drug
pipeline comprises 11 clinical (Phase I-III) development programmes: ACR16 in
Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase
III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in
partnership with GSK, NS1209 in epilepsy and pain (Phase II), ABT-894 in ADHD
(Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in
schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar
disorder and Parkinson's disease (Phase I) and ABT-107 as well as ABT-560 for
the treatment of various CNS diseases - both (Phase I) in collaboration with
Abbott. In addition, NeuroSearch has a broad portfolio of preclinical drug
candidates and holds equity interests in several biotech companies.